Alliancebernstein L.P. raised its position in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by 31.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 640,654 shares of the biotechnology company’s stock after purchasing an additional 153,617 shares during the period. Alliancebernstein L.P. owned 2.31% of Audentes Therapeutics worth $12,256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Sphera Funds Management LTD. purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $2,870,000. Jennison Associates LLC increased its position in shares of Audentes Therapeutics by 182.4% in the 2nd quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after purchasing an additional 546,617 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Audentes Therapeutics by 180.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 34,057 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $210,000. Finally, Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $252,000. 77.01% of the stock is currently owned by institutional investors.

In related news, SVP David Nagler sold 3,750 shares of Audentes Therapeutics stock in a transaction on Friday, September 15th. The shares were sold at an average price of $25.00, for a total value of $93,750.00. Following the completion of the sale, the senior vice president now owns 3,750 shares in the company, valued at $93,750. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction on Friday, September 1st. The stock was sold at an average price of $21.44, for a total transaction of $171,520.00. Following the completion of the sale, the vice president now owns 8,000 shares of the company’s stock, valued at approximately $171,520. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,600 shares of company stock valued at $1,184,620. Insiders own 47.30% of the company’s stock.

Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 27.31 on Monday. Audentes Therapeutics, Inc. has a 52-week low of $13.13 and a 52-week high of $28.63. The stock’s market capitalization is $758.78 million. The company has a 50 day moving average of $24.77 and a 200-day moving average of $24.77.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). Equities research analysts anticipate that Audentes Therapeutics, Inc. will post ($3.50) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics, Inc. (BOLD) Holdings Raised by Alliancebernstein L.P.” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/25/audentes-therapeutics-inc-bold-holdings-raised-by-alliancebernstein-l-p.html.

A number of equities research analysts have commented on the stock. ValuEngine downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Evercore ISI assumed coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, Bank of America Corporation increased their price objective on shares of Audentes Therapeutics from $23.00 to $33.00 and gave the company a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Audentes Therapeutics presently has a consensus rating of “Buy” and an average target price of $24.17.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.